Overview

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Collaborators:

Beijing Biostar Technologies, Ltd
Qilu Pharmaceutical Co., Ltd.

Treatments:

Bevacizumab